ArticlePituitary2011
The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas.
Article in Pituitary, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- Expression of MMP-2, MMP-9 and TIMP-2 in pituitary tumors and their relationship with cavernous sinus invasion.Endocrine oncology (Bristol, England) · 2025Article
- Analysis of gut microbiota-derived metabolites regulating pituitary neuroendocrine tumors through network pharmacology.Frontiers in pharmacology · 2024Article
- Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment.Frontiers in neuroscience · 2024Review
- Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.Cancers · 2023Review
- Tumour microenvironment and pituitary tumour behaviour.Journal of endocrinological investigation · 2023Review
- The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications.Pituitary · 2022Review
- Aggressive pituitary tumours and pituitary carcinomas.Nature reviews. Endocrinology · 2021Review
- Loss of Interleukin-17RA Expression is Associated with Tumour Progression in Colorectal Carcinoma.Pathology oncology research : POR · 2020Article
- The Pituitary Tumors and Their Tumor-Specific Microenvironment.Advances in experimental medicine and biology · 2020Article
- Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.Acta neuropathologica communications · 2019Article
- Molecular Network Basis of Invasive Pituitary Adenoma: A Review.Frontiers in endocrinology · 2019Review
- Role of matrix Metalloproteinases in pituitary adenoma invasion.Chinese neurosurgical journal · 2018Review
- Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu.Frontiers in immunology · 2018Review
- Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma.BioMed research international · 2018Article
- Lactate dehydrogenase A promotes the invasion and proliferation of pituitary adenoma.Scientific reports · 2017Article
- Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification.Endocrine pathology · 2016Review
- Prognostic significance of interleukin-17 in solid tumors: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Factors influencing improvement of visual field after trans-sphenoidal resection of pituitary macroadenomas: a retrospective cohort study.International journal of ophthalmology · 2015Article
- Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas.Pituitary · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The IL-17 plays a crucial role in the invasion of tumors. However, the effects of IL-17 on the invasion of human pituitary adenomas are still unknown. The current study is designed to investigate the possible involvement of IL-17 in the invasion of adenomas. By collecting invasive and non-invasive pituitary adenomas, the mRNA and protein levels of IL-17, IL-17R and MMP-9 are investigated. The results obtained from IHC showed that the strong positive rate and the total positive rate of IL-17, IL-17R and MMP-9 expression cells in the non-invasive group were 17.1 and 51.43%, 14.3 and 54.3%, 17.1 and 57.1%, respectively. In contrast, the strong positive rate and the total positive rate of the invasive group were significantly higher than that of the non-invasive group, which were 37.5 and 82.5%, 52.5 and 87.5%, 67.5 and 92.5%, respectively. Meanwhile, the serum IL-17 level in the invasive pituitary adenomas patients was significantly higher than in the non-invasive groups (P < 0.05). Furthermore, the mRNA levels of IL-17, IL-17R and MMP-9 were also higher in the invasive group than in the non-invasive group with statistical differences (P < 0.05), and where the expression levels of IL-17 and IL-17R had positive correlation with that of MMP-9 in the invasive group. These results suggested that IL-17 may promote the invasion of pituitary adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.